Development and evaluation of an experimental model for investigating the pathogenesis and therapeutic strategies of acute liver failure.
Because of the various etiologies of acute liver failure (ALF) a clinically relevant model must fulfill four criteria--reversibility, reproducibility, ALF-induced death, and a sufficient time interval for diagnosis and therapy between induction and death. In this study an experimental model was evaluated for these criteria. A total of 49 rats were randomized into seven groups: First, a pilot study was performed regarding the survival rate after different treatments: In group I, animals underwent a 70% liver resection. In group II, 70% liver resection was combined with ascending doses of postoperative endotoxin administration up to 400 microg/kg (group IIc). In group III, animals only underwent liver mobilization. In group IV, ALF was induced according to the protocol of group IIc, but with additional treatment of an endothelin-A-receptor (ETAR) antagonist. Animals in group V received only 400 microg endotoxin. After induction of ALF, all animals died within the first day, showing significantly elevated bilirubin and ammonium levels and severe damage to hepatocellular integrity. Application of the ETAR antagonist resulted in the survival of 6/7 animals until the 14th day; the biochemical and histomorphological changes were reversible. All other animals survived to the 14th day. A clinically relevant model of ALF in rats can be created by the combination of 70% liver resection and endotoxin application to produce an inflammatory component.
Skawran
S
S
Department of Surgery, Münster University Hospital, Waldeyer Strasse 1, 48149 Münster, Germany.
Palmes
D
D
Budny
T
T
Bahde
R
R
Stratmann
U
U
Spiegel
H U
HU
D000208:Acute Disease; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001663:Bilirubin / Q000097:blood; D004195:Disease Models, Animal; D005260:Female; D006498:Hepatectomy; D008102:Liver Circulation / Q000502:physiology; D017093:Liver Failure / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D008115:Liver Regeneration; D008833:Microcirculation / Q000502:physiology; D010865:Pilot Projects; D051381:Rats; D017208:Rats, Wistar; D016019:Survival Analysis
D000410:Alanine Transaminase; D001663:Bilirubin